// App-Quantinova.ai

P193 : Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies

Researchers

Presenter

  • Karl Gaffney

Principal Investigators

  • Neil McKay

  • Raj Sengupta

  • Carmen Fleurinck

  • Christine de la Loge

  • Ute Massow

  • Vanessa Taieb

  • Sizheng Steven Zhao

  • Helena Marzo-Ortega

Medical Centers

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Immunology, UCB Pharma, Brussels, BELGIUM

  • Edinburgh Rheumatology Research Group, NHS Lothian, Edinburgh, United Kingdom

  • Rheumatology, UCB Pharma, Monheim am Rhein, Germany

  • Paediatrics, Norfolk and Norwich University Hospitals NHS Foundation Trust,Norwich, United Kingdom

  • Rheumatology, UCB Pharma, Colombes, France

  • Department of Rheumatology, North Manchester General Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom

  • Rheumatology, PCOM Analytics, Avallon, France

Locations

  • United Kingdom

  • France

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved